Immunome submitted an NDA to the FDA for varegacestat in desmoid tumors after the Phase 3 RINGSIDE trial showed an 84% reduction in progression risk (HR=0.16) and a 56% objective response rate. The company plans to file in Q2 2026.
A study published in Science sequenced cancer-related genes in 493 cat tumor samples across 13 cancer types, revealing striking genetic similarities with human cancers and opening possibilities for shared treatments.
Researchers have developed modified CAR T cells that overcome prostaglandin E2 suppression in solid tumors and a selective therapy targeting IGHV4-34 that spares healthy immune cells, addressing key limitations in current treatments.
A case report published in Oncotarget details a 38-year-old woman who developed acute lymphoblastic leukemia and lymphoblastic lymphoma shortly after receiving her second Pfizer-BioNTech mRNA vaccine dose, prompting calls for further investigation into potential immune-related mechanisms.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07002099 |
Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma: An Open-label, Single-arm, Multicenter Phase II Study |
RECRUITING | PHASE2 |
| NCT06647329 |
CAR-T Technology for Recurrent/Refractory Malignant Hematological and Lymphatic Tumors |
NOT_YET_RECRUITING | PHASE1 |
| NCT06148220 |
A Study of the Clinical Application of [18F]RCCB6 and [68Ga]Ga-NOTA-RCCB6 PET/CT Imaging in the Diagnosis of CD70-expressing Multiple Tumors |
RECRUITING | NA |
| NCT05775406 |
Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors |
COMPLETED | PHASE1 |
| NCT05773040 |
A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas |
RECRUITING | PHASE1 |
| NCT04417803 |
Interest of Individual Biomarkers From the Identification of Tumor Genotype by High-throughput Molecular Techniques |
RECRUITING | NA |
| NCT03128164 |
A Study of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or no Standard of Care Existed |
COMPLETED | PHASE1 |
| NCT02902237 |
tTF-NGR Phase I Study |
COMPLETED | PHASE1 |
| NCT02786485 |
Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT |
WITHDRAWN | PHASE1 |
| NCT02740270 |
Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas |
COMPLETED | PHASE1 |
